Sartorius AG (0NIQ) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the presentation of Sartorius and Sartorius Stadium Biotech's 9-month 2025 results. Please note that the call is being recorded and streamed on Sartorius' website. Your participation in this implies your consent with this. A replay will be available shortly after the call. I would now like to turn the conference over to Petra Müller, Head of Investor Relations of Sartorius. Hello, thank you, Matilda, and a warm welcome from my side. I'm joined today by our CEO, Michael Große, by Florian Funk, our CFO, by René Faber, head of our Bioprocessing Division and CEO of Sartorial State and Biotech, and by Alexandra Gatzemeier, head of our Lab Products and Services Division. As always, we will start with prepared remarks followed by a Q&A session. As the call is scheduled for one hour, please limit your questions to two so that as many participants as possible can take part. Please note that management comments during this call will include forward-looking statements that involve risks and uncertainties for discussion of the risk factors. I encourage you to review the safe harbor statement contained in our today's documents. All of these are relating to our nine-month figures, and the reporting are available on the website. And with that, I'm pleased to hand over to Michael Grosse, CEO of Sartorius. Michael, the floor is yours. Thank you so much, Petra, and good afternoon, everyone. A very warm welcome also from my side, and thank you for joining us today. As usual, we will walk you through our operational and financial performance year-to-date, discuss our updated outlook, and for the remainder of the year. Before we drive into the details, let me share a few remarks on my first three months as the CEO of Sartorius AG. Over the past weeks and months, I focused trul...